PT  - JOURNAL ARTICLE
AU  - Corradini, Paolo
AU  - Agrati, Chiara
AU  - Apolone, Giovanni
AU  - Mantovani, Alberto
AU  - Giannarelli, Diana
AU  - Marasco, Vincenzo
AU  - Bordoni, Veronica
AU  - Sacchi, Alessandra
AU  - Matusali, Giulia
AU  - Salvarani, Carlo
AU  - Zinzani, Pier Luigi
AU  - Mantegazza, Renato
AU  - Tagliavini, Fabrizio
AU  - Lupo-Stanghellini, Maria Teresa
AU  - Ciceri, Fabio
AU  - Damian, Silvia
AU  - Uccelli, Antonio
AU  - Fenoglio, Daniela
AU  - Silvestris, Nicola
AU  - Baldanti, Fausto
AU  - Piaggio, Giulia
AU  - Ciliberto, Gennaro
AU  - Morrone, Aldo
AU  - Locatelli, Franco
AU  - Sinno, Valentina
AU  - Rescigno, Maria
AU  - Costantini, Massimo
AU  - ,
TI  - Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study
AID  - 10.1101/2022.01.12.22269133
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.12.22269133
4099  - http://medrxiv.org/content/early/2022/01/13/2022.01.12.22269133.short
4100  - http://medrxiv.org/content/early/2022/01/13/2022.01.12.22269133.full
AB  - Background Patients with solid or hematological tumors, neurological and immune-inflammatory disorders represent potentially fragile subjects with increased risk to experience severe COVID-19 and inadequate response to SARS-CoV2 vaccination.Methods We designed a prospective Italian multicentric study to assess humoral and T-cell response to SARS-CoV2 vaccination in patients (n=378) with solid tumors (ST), hematological malignancies (HM), neurological (ND) and immuno-rheumatological diseases (ID). The immunogenicity of primary vaccination schedule and of the booster dose were analyzed.Results Overall, patient seroconversion rate after two doses was 62.1%. A significant lower rate was observed in HM (52.4%) and ID (51.9%) patients compared to ST (95.6%) and ND (70.7%); a lower median level of antibodies was detected in HM and ID versus the others (p<0.0001). A similar rate of patients with a positive SARS-CoV2 T-cell response was observed in all disease groups, with a higher level observed in the ND group. The booster dose improved humoral responses in all disease groups, although with a lower response in HM patients, while the T-cell response increased similarly in all groups. In the multivariable logistic model, the independent predictors for seroconversion were disease subgroups, type of therapies and age. Notably, the ongoing treatment known to affect the immune system was associated with the worst humoral response to vaccination (p<0.0001), but had no effects on the T-cell responses.Conclusions Immunosuppressive treatment more than disease type per se is a risk factor for low humoral response after vaccination. The booster dose can improve both humoral and T-cell response.Article’s main point- Lower rate of seroconversion was observed in fragile patients as compared to healthy controls- The booster dose improves humoral and T-cell response in all fragile patient groups- Immunosuppressive treatment was associated with the worst humoral response to vaccination, but had no effects on T-cell responses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Italian ministry of HealthAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Italian Regulatory Agency (AIFA) and by the Ethics Committee of IRCCS L. Spallanzani (code 304, 2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors